Your browser doesn't support javascript.
loading
Comprehensive characterization of protein-protein interactions perturbed by disease mutations.
Cheng, Feixiong; Zhao, Junfei; Wang, Yang; Lu, Weiqiang; Liu, Zehui; Zhou, Yadi; Martin, William R; Wang, Ruisheng; Huang, Jin; Hao, Tong; Yue, Hong; Ma, Jing; Hou, Yuan; Castrillon, Jessica A; Fang, Jiansong; Lathia, Justin D; Keri, Ruth A; Lightstone, Felice C; Antman, Elliott Marshall; Rabadan, Raul; Hill, David E; Eng, Charis; Vidal, Marc; Loscalzo, Joseph.
Afiliação
  • Cheng F; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Zhao J; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
  • Wang Y; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Lu W; Department of Systems Biology, Herbert Irving Comprehensive Center, Columbia University, New York, NY, USA.
  • Liu Z; Department of Biomedical Informatics, Columbia University, New York, NY, USA.
  • Zhou Y; Center for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Martin WR; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Wang R; Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
  • Huang J; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
  • Hao T; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Yue H; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Ma J; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Hou Y; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, China.
  • Castrillon JA; Center for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Fang J; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Lathia JD; Center for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Keri RA; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
  • Lightstone FC; Center for Cancer Systems Biology (CCSB), Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Antman EM; Research Center for Healthcare Data Science, Zhejiang Lab, Hangzhou, Zhejiang, China.
  • Rabadan R; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Hill DE; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Eng C; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Vidal M; Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
  • Loscalzo J; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Nat Genet ; 53(3): 342-353, 2021 03.
Article em En | MEDLINE | ID: mdl-33558758
ABSTRACT
Technological and computational advances in genomics and interactomics have made it possible to identify how disease mutations perturb protein-protein interaction (PPI) networks within human cells. Here, we show that disease-associated germline variants are significantly enriched in sequences encoding PPI interfaces compared to variants identified in healthy participants from the projects 1000 Genomes and ExAC. Somatic missense mutations are also significantly enriched in PPI interfaces compared to noninterfaces in 10,861 tumor exomes. We computationally identified 470 putative oncoPPIs in a pan-cancer analysis and demonstrate that oncoPPIs are highly correlated with patient survival and drug resistance/sensitivity. We experimentally validate the network effects of 13 oncoPPIs using a systematic binary interaction assay, and also demonstrate the functional consequences of two of these on tumor cell growth. In summary, this human interactome network framework provides a powerful tool for prioritization of alleles with PPI-perturbing mutations to inform pathobiological mechanism- and genotype-based therapeutic discovery.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 Base de dados: MEDLINE Assunto principal: Biologia Computacional / Mapas de Interação de Proteínas / Mutação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Genet Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 Base de dados: MEDLINE Assunto principal: Biologia Computacional / Mapas de Interação de Proteínas / Mutação / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Genet Ano de publicação: 2021 Tipo de documento: Article